{"filings":[{"id":483157,"accession_number":"0001193125-26-228003","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2026-05-18T13:01:36+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ligand and XOMA Royalty amend merger agreement to add HoldCo as party","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 1 dated May 16, 2026, adds XOMA Royalty Holdings Corp as a party to the merger agreement.","HoldCo was formed on May 15, 2026 to facilitate the holding company reorganization under Nevada law.","Changes are technical, including joinder of HoldCo and minor section amendments; deal value/terms unchanged.","The merger was previously announced on April 27, 2026; transaction conditions remain the same."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99460,"accession_number":"0000886163-26-000030","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q1 royalty revenue +56% to $43M; reaffirms raised guidance amid XOMA acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 royalty revenue $43.0M (+56% YoY); total revenue $51.7M (+14%).","GAAP net loss $13.3M ($0.67/sh) vs loss $42.5M ($2.21/sh) prior yr; adj EPS $1.63 (+23%).","Reaffirms FY2026 guidance: royalty rev $225-250M, total rev $270-310M, adj EPS $8.50-9.50.","Acquiring XOMA for $39/share in cash + CVR; adds over 120 assets incl. Vabysmo, Ojemda, Miplyffa.","Cash and investments $779.4M at Mar 31; deal expected to close Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":51722000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99459,"accession_number":"0000886163-26-000027","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Ligand terminates TR-Beta license with Viking over alleged material breach; Viking disputes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination of TR-Beta Program (including VK2809 and VK0214) effective May 4, 2026.","Ligand asserts Viking materially breached obligation to use commercially reasonable efforts.","Viking disputes termination; Ligand intends to vigorously enforce its termination rights.","Upon termination, licenses revert to Ligand; Viking must grant non-exclusive worldwide royalty-bearing license at low single digits royalty rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99458,"accession_number":"0001193125-26-179529","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ligand to acquire XOMA Royalty for $39/share cash plus CVR from Janssen litigation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $39.00 per XOMA Royalty share plus CVRs representing 75% of net proceeds from Janssen litigation.","Support agreements from stockholders (~47% of shares), including BFV Partners and management, to vote in favor.","Termination fee of $40M payable by XOMA Royalty under specified circumstances.","Transaction subject to XOMA Royalty stockholder approval and HSR clearance; expected to close by Jan 26, 2027.","XOMA Royalty board unanimously approved and recommends stockholders vote in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115468,"accession_number":"0000886163-26-000003","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q4 revenue $59.7M (+39% YoY), adjusted EPS $2.02 beats; FY25 core adj. EPS $8.13, +42%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income $44.8M ($2.12 diluted EPS) vs loss of $31.1M in Q4 2024.","Full year 2025 royalty revenue $161.0M (+48% YoY); total revenue $268.1M (+60% YoY).","Cash and short-term investments $733.5M at Dec 31, 2025; 2026 guidance reaffirmed: rev $245-285M, adj. EPS $8.00-9.00.","Filspari Q4 net sales $103M (+108% YoY); new patient starts all-time high of 908.","Palvella Phase 3 SELVA (Qtorin rapamycin) met primary endpoint; NDA submission H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":6.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":268087000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131893,"accession_number":"0001193125-25-324830","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Ligand discloses private placement investment in Athira Pharma","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Private placement investment in Athira Pharma, Inc. announced via social media and IR page.","No financial terms, size, or pricing disclosed in the 8-K filing.","Ligand directs investors to its website and social media for further details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131892,"accession_number":"0000886163-25-000058","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q3 revenue $115.5M, net income $117.3M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 royalties $46.6M, up 47% YoY, driven by Filspari, Ohtuvayre, Qarziba.","Adjusted EPS $3.09 vs $1.84 YoY; GAAP net income $117.3M ($5.68 diluted).","FY 2025 core revenue guidance raised to $225M-$235M; core adj. EPS $7.40-$7.65.","Closed $460M 0.75% convertible notes due 2030; net proceeds ~$445M.","New royalty investments: $7M for AT220/AT292 rights; $25M in Orchestra BioMed."],"consensus_eps_estimate":null,"consensus_eps_actual":3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":208421000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148474,"accession_number":"0001193125-25-205147","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Ligand Pharmaceuticals extends credit facility maturity to Sept 2028, sets minimum EBITDA at $55M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Amendment to Credit Agreement dated Sep 12, 2025 extends maturity to September 12, 2028.","New minimum consolidated EBITDA covenant: not less than $55 million for trailing four-quarter periods.","Amendment modifies credit agreement originally dated Oct 12, 2023, with all Lenders consenting.","Borrower reaffirmed obligations and Guarantors reaffirmed guarantees under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148473,"accession_number":"0001193125-25-180841","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Ligand closes $460M 0.75% convertible notes due 2030; net proceeds $445.1M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $460M aggregate principal of 0.75% convertible senior notes due Oct 1, 2030, including $60M greenshoe exercised.","Initial conversion price ~$194.79/share (32.5% premium over Aug 11 closing price of $147.01).","Net proceeds ~$445.1M; used $45.9M for convertible note hedge, $15M to repurchase 102,034 shares at $147.01/share.","Also entered separate warrant transactions covering ~2.36M shares at strike $294.02/share, potentially dilutive.","Notes may be redeemed at option on/after Oct 6, 2028 if stock >=130% of conversion price for 20 trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148472,"accession_number":"0001193125-25-177452","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ligand proposes $400M convertible notes due 2030; up to $60M greenshoe","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering $400M aggregate principal amount of convertible senior notes due Oct 1, 2030 to QIBs.","Initial purchasers have 13-day option to buy up to an additional $60M of notes.","Up to $30M of net proceeds used to repurchase common stock from note purchasers.","Remaining net proceeds for general corporate purposes, including potential acquisitions.","Convertible note hedge and warrant transactions entered to manage dilution and offset cash payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148471,"accession_number":"0000886163-25-000047","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q2 royalties up 57% to $36.4M; raises FY2025 guidance to $200-225M revenue and $6.70-7.00 adj. EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $47.6M (+15% YoY); royalties $36.4M (+57%) driven by Qarziba and Filspari.","GAAP net income $4.8M ($0.24 diluted) vs loss $51.9M in Q2 2024; core adj. EPS $1.60 vs $1.40.","FY2025 guidance raised: revenue $200-225M (prev $180-200M), adj. EPS $6.70-7.00 (prev $6.00-6.25).","Pelthos merger closed; Zelsuvmi launched July 10; Ligand earned $5M milestone and 13% royalty.","Merck acquiring Verona for ~$10B; Ligand holds 3% royalty on Ohtuvayre (COPD)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":92960000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148470,"accession_number":"0000886163-25-000042","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ligand completes merger with Channel Therapeutics; Pelthos starts trading July 2 under PTHS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ligand subsidiary merges with Channel; combined company renamed Pelthos Therapeutics, trading on NYSE American as PTHS.","Ligand invests $18M in Pelthos; entitled to 13% royalty on worldwide net sales of ZELSUVMI.","Pelthos raises total $50.1M equity from Ligand and Murchinson-led investor group.","ZELSUVMI (berdazimer) topical gel, FDA-approved for molluscum, to launch July 2025; first at-home prescription treatment.","Pelthos to also evaluate Channel's NaV 1.7 pain development programs for chronic pain and eye pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167296,"accession_number":"0000886163-25-000040","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ligand shareholders re-elect all eight directors, ratify auditor, and approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected, with each receiving >15.5M votes for (excluding broker non-votes).","Ratification of Ernst & Young as independent auditor for FY2025 passed with 17.27M votes for.","Non-binding advisory vote on named executive officer compensation approved with 15.58M votes for.","Broker non-votes totaled 1.36M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167295,"accession_number":"0000886163-25-000033","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q1 revenue up 46% to $45.3M; core adjusted EPS $1.33; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $45.3M (+46% YoY), royalties $27.5M (+44%), Captisol $13.5M (+47%).","GAAP net loss $42.5M ($2.21/sh) includes $44.3M one-time R&D charge for Castle Creek; core adjusted net income $26.6M ($1.33/sh).","Reaffirms FY2025 guidance: revenue $180-200M, adjusted EPS $6.00-$6.25.","Pelthos to merge with Channel Therapeutics (NYSE: PTHS) backed by $50M capital; expected close summer 2025.","Led $50M of $75M Castle Creek royalty financing for D-Fi Phase 3; net mid-single digit royalty."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":45333000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167294,"accession_number":"0000886163-25-000020","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ligand subsidiary Pelthos to merge with Channel Therapeutics; $50M capital raise","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Channel to acquire 100% of Pelthos; combined company renamed Pelthos Therapeutics, listing as PTHS on NYSE American.","Total $50M equity raised: $18M from Ligand, $32M from Murchinson-led investor group.","Ligand retains 13% royalty on worldwide sales of ZELSUVMI, FDA-approved for Molluscum contagiosum.","Scott Plesha to become CEO, Frank Knuettel CFO; board includes two Ligand appointees.","Transaction expected to close summer 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184623,"accession_number":"0000886163-25-000008","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q4 revenue up 52% to $42.8M; core adj EPS $1.27; reaffirms 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total rev $42.8M (+52% YoY); royalties $34.8M (+55%) driven by Qarziba and Filspari.","Core adjusted net income from cont ops $25.2M ($1.27/diluted) vs $18.6M ($1.05) prior year.","Full year adj net income $156.0M ($8.25/diluted); core adj $108.5M ($5.74/diluted).","Reaffirms 2025 guidance: total rev $180-200M, adjusted EPS $6.00-$6.25.","Closed $50M royalty investment in Castle Creek Biosciences for D-Fi Phase 3 study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":167133000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184622,"accession_number":"0000886163-25-000003","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ligand leads $75M royalty financing for Castle Creek's D-Fi gene therapy Phase 3 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ligand invested $50M and led syndicate of co-investors totaling $75M for high single-digit royalty on D-Fi worldwide sales.","Castle Creek to use funds for Phase 3 trial of D-Fi (gene therapy) for dystrophic epidermolysis bullosa (DEB).","Ligand also acquired $8.3M subordinated promissory note for $1.8M, due upon FDA approval of D-Fi.","Co-investors include Paragon Biosciences, Valor Equity Partners, and XOMA Royalty Corp. (Nasdaq: XOMA).","Warrants to purchase Series D-1 Preferred Shares exercisable until 2035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201207,"accession_number":"0000886163-24-000074","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q3 revenue $51.8M (+58% YoY); raises 2024 guidance to $160-165M revenue, $5.50-5.70 adj EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenues & other income $51.8M (vs $32.9M); royalties $31.7M (+33% YoY) on QARZIBA and FILSPARI growth.","GAAP net loss from continuing ops $7.2M ($0.39 loss/sh); core adj net income $35.3M ($1.84/sh) vs $18.0M ($1.02).","Raised 2024 guidance: revenue now $160-165M (prev $140-157M); adj EPS $5.50-5.70 (prev $5.00-5.50).","Received $13.5M milestone upon Ohtuvayre commercial launch; cash & investments $219.6M including $63.3M in VKTX stock.","Issued 334,325 shares under ATM at avg $104.70 for gross $35M; up to $65M remains available."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":124321000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217231,"accession_number":"0000886163-24-000067","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q2 revenue rises 57% to $41.5M; GAAP net loss $51.9M on $33.8M Primrose Bio writedown","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $41.5M (+57% YoY); royalties $23.2M (+11%); Captisol $7.5M (+44%).","GAAP net loss from continuing ops $51.9M ($2.88/sh) vs income $2.3M ($0.13) YoY; adjusted net income $25.8M ($1.40).","Core adjusted net income $25.8M vs $11.7M YoY, excluding Viking stock sales and non-cash impairments.","2024 guidance reaffirmed: royalties $100-105M, total revenue $140-157M, core adj. EPS $5.00-$5.50.","Completed $100M APEIRON Biologics acquisition (July 8); credit facility expanded to $125M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":72509000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217230,"accession_number":"0000886163-24-000064","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ligand Pharmaceuticals announces departure of President and COO Matthew Korenberg","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Korenberg's employment ends no later than October 31, 2024; he may resign earlier in writing.","Severance includes base salary through termination, 50% of 2024 target bonus, and COBRA coverage through Dec 31, 2024.","Post-termination consulting agreement pays $47,808/mo through Oct 31, 2024, then reduced amounts.","Stock award vesting continues through consulting period; unvested awards through Dec 31, 2025 accelerate on consulting end.","Korenberg can exercise stock awards through March 1, 2026, subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217229,"accession_number":"0000886163-24-000061","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Ligand completes acquisition of APEIRON Biologics for $100M cash plus up to $28M contingent","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ligand acquired all outstanding shares of APEIRON for $100M in cash at closing on July 15, 2024.","Additional contingent consideration up to $28M if QARZIBA royalties exceed predetermined thresholds by 2030 or 2034.","QARZIBA (dinutuximab beta) is approved for high-risk neuroblastoma; Ligand obtains royalty rights.","Acquisition funded from Ligand's available cash on hand; closing subject to 30-day shareholder objection period.","Deal structured as a definitive agreement first announced on July 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217228,"accession_number":"0000886163-24-000059","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Ligand ups revolving credit line to $125M from $75M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First amendment to Oct 2023 Credit Agreement executed July 8, 2024, increasing aggregate revolving commitments from $75M to $125M.","Borrowing capacity expanded by $50M; no other material changes detailed in the filing.","Credit facility includes subsidiaries as guarantors; Citibank remains administrative agent, swingline lender and L/C issuer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217227,"accession_number":"0000886163-24-000053","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ligand acquires APEIRON for $100M, adds QARZIBA royalty; raises 2024 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of APEIRON Biologics for $100M cash; up to $28M additional contingent consideration based on QARZIBA royalty thresholds by 2030/2034.","QARZIBA is approved in EU for high-risk neuroblastoma, marketed in >35 countries by Recordati; patent protection until 2034.","Transaction expected to close July 2024; subject to 30-day shareholder objection period and other customary conditions.","Ligand raises 2024 revenue guidance to $140M-$157M (from $130M-$142M) and core adjusted EPS to $5.00-$5.50 (from $4.25-$4.75).","Deal immediately accretive to EPS by ~$1.00 annualized; ~$0.50 impact in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237017,"accession_number":"0000886163-24-000051","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Partner Verona Pharma gets FDA approval for Ohtuvayre (COPD); Ligand earns $5.8M milestone, $13.8M at launch","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Ohtuvayre (ensifentrine) for maintenance treatment of COPD in adults; first novel inhaled mechanism in over 20 years.","Ligand earned a $5.8 million milestone payment; additional $13.8 million due upon commercial launch expected in Q3 2024.","Ligand is entitled to a low single-digit royalty on potential worldwide net sales of Ohtuvayre; COPD market is multi-billion dollar.","Verona Pharma is responsible for commercialization; Ligand relies on Verona for successful launch and sales.","Approval triggers immediate milestone and sets stage for further payments and ongoing royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237016,"accession_number":"0000886163-24-000047","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ligand reports Merck vaccine FDA approval milestone and Takeda soticlestat Phase 3 miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved Merck's CAPVAXIVE; Ligand earns $2M milestone + royalties on net sales.","Takeda's soticlestat missed primary endpoints in Dravet (SKYLINE) and Lennox-Gastaut (SKYWAY) Phase 3 trials.","Ligand owns 13% royalty on soticlestat from $30M Ovid deal; clinical miss reduces royalty value.","SKYLINE narrowly missed seizure reduction primary; showed significant secondary endpoint effects.","SKYWAY missed primary endpoint of reduction in major motor drop seizures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237015,"accession_number":"0000886163-24-000045","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Shareholders approve 9.7M share stock plan amendment, re-elect all eight directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees re-elected to one-year terms; votes for ranged from 12.3M to 15.3M.","Ratification of Ernst & Young as independent auditor for FY2024 approved (15.9M for, 0.8M against).","Non-binding advisory say-on-pay resolution approved with 14.3M votes for.","Restated 2002 Stock Incentive Plan approved, authorizing up to 9,713,754 common shares.","Company will cease granting awards under the 2022 Employment Inducement Plan after meeting date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237014,"accession_number":"0000886163-24-000039","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ligand completes $75M purchase of Agenus royalty rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed purchase of royalty rights from Agenus Inc. for $75M on May 29, 2024.","Transaction previously announced on May 7, 2024; customary closing conditions satisfied.","No other terms or financial impact disclosed beyond the purchase price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237013,"accession_number":"0000886163-24-000029","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand reports Q1 revenue $31M; net income $86.1M on Viking gain; reaffirms guidance; $100M Agenus royalty deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $31.0M vs $44.0M last year; royalties up $19.1M from $17.6M.","Net income $86.1M ($4.75 diluted) vs $43.6M, includes $60M realized gain on Viking stock.","Core adjusted EPS $1.20 vs $1.33; decrease due to prior-year $15.3M Travere milestone.","Reaffirms 2024 guidance: total revenue $130-142M, core adjusted EPS $4.25-4.75.","Entered $100M royalty financing with Agenus for six partnered oncology programs; $75M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":4.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":30978000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237012,"accession_number":"0000886163-24-000026","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Ligand acquires royalty rights on six partnered oncology programs and BOT/BAL from Agenus for $75M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $75M for 18.75% of licensed royalties and 31.875% of milestones on six partnered oncology programs (BMS, Gilead, Incyte, Merck, UroGen).","Plus synthetic 2.625% royalty on future global net sales of Agenus' botensilimab/balstilimab (BOT/BAL) program.","Ligand has option to commit additional $25M on pro rata basis; Sellers may raise up to $125M more total.","Agenus issued Ligand warrant to purchase 867,052 shares of AGEN common stock at $17.30, exercisable until May 2029.","Transaction expected to close in May 2024 subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237011,"accession_number":"0000886163-24-000013","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ligand adopts amended bylaws for universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Fifth Amended and Restated Bylaws on April 17, 2024.","Updates include requirements for stockholder nominations under Rule 14a-19 (universal proxy).","Clarifies broker non-votes have no effect; abstentions count as votes against.","Revisions reflect changes to Delaware General Corporation Law on electronic notices and stockholder lists.","Also makes conforming changes to stockholder proposal and nomination procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254599,"accession_number":"0000886163-24-000005","cik":886163,"company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGND","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ligand Q4 net income $18.2M ($1.03 diluted); reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $28.1M (down from $50.4M in Q4 2022, which included $23.5M COVID Captisol sales); core adjusted EPS $1.05 vs $0.75.","Full-year 2023 royalties $83.9M (+16% YoY); core adjusted net income $71.7M ($4.06/diluted) vs $41.9M ($2.44).","2024 guidance reaffirmed: total revenue $130-142M, adjusted EPS $4.25-4.75.","FDA approved ZELSUVMI (berdazimer gel) for molluscum contagiosum; Merck's V116 vaccine granted priority review (PDUFA June 17, 2024).","Travere's FILSPARI sNDA for IgAN planned Q1 2024; FSGS data insufficient; Aldeyra received CRL for reproxalap."],"consensus_eps_estimate":null,"consensus_eps_actual":2.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":131314000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4727486010.471422,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}